|
1
|
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
|
J Clin Oncol
|
2009
|
5.37
|
|
2
|
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
|
J Clin Oncol
|
2004
|
4.69
|
|
3
|
Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility.
|
Gynecol Oncol
|
2007
|
2.32
|
|
4
|
Resource utilization for ovarian cancer patients at the end of life: how much is too much?
|
Gynecol Oncol
|
2005
|
2.26
|
|
5
|
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
|
Gynecol Oncol
|
2009
|
2.26
|
|
6
|
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.
|
Cancer Res
|
2009
|
2.23
|
|
7
|
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
|
Gynecol Oncol
|
2007
|
2.20
|
|
8
|
Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.
|
J Clin Oncol
|
2014
|
2.05
|
|
9
|
Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.
|
Int J Radiat Oncol Biol Phys
|
2009
|
2.05
|
|
10
|
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins.
|
Gynecol Oncol
|
2013
|
2.01
|
|
11
|
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
|
J Clin Oncol
|
2007
|
1.87
|
|
12
|
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.
|
Proc Natl Acad Sci U S A
|
2003
|
1.83
|
|
13
|
Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
|
Cancer
|
2014
|
1.80
|
|
14
|
Use of complementary and alternative medicine among women with gynecologic cancers.
|
Gynecol Oncol
|
2002
|
1.72
|
|
15
|
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome.
|
Cancer
|
2005
|
1.68
|
|
16
|
Retrorectal tumors: a diagnostic and therapeutic challenge.
|
Dis Colon Rectum
|
2005
|
1.65
|
|
17
|
Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.
|
Gynecol Oncol
|
2009
|
1.59
|
|
18
|
Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?
|
Gynecol Oncol
|
2002
|
1.57
|
|
19
|
Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.
|
Clin Cancer Res
|
2011
|
1.57
|
|
20
|
Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53.
|
Gynecol Oncol
|
2004
|
1.57
|
|
21
|
Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.
|
Am J Hum Genet
|
2004
|
1.57
|
|
22
|
Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
|
J Clin Oncol
|
2010
|
1.55
|
|
23
|
A multi-institutional review of outcomes of endometrial stromal sarcoma.
|
Gynecol Oncol
|
2007
|
1.53
|
|
24
|
Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.
|
J Natl Cancer Inst
|
2013
|
1.52
|
|
25
|
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
|
PLoS One
|
2012
|
1.45
|
|
26
|
Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy.
|
Gynecol Oncol
|
2005
|
1.45
|
|
27
|
Evidence for heritable predisposition to epigenetic silencing of MLH1.
|
Int J Cancer
|
2007
|
1.43
|
|
28
|
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
|
J Clin Oncol
|
2006
|
1.41
|
|
29
|
Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.39
|
|
30
|
Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy.
|
Cancer
|
2007
|
1.38
|
|
31
|
Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma.
|
Clin Cancer Res
|
2003
|
1.36
|
|
32
|
Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer.
|
Gynecol Oncol
|
2011
|
1.34
|
|
33
|
Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing.
|
Nucleic Acids Res
|
2009
|
1.26
|
|
34
|
ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
|
J Clin Oncol
|
2009
|
1.25
|
|
35
|
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography.
|
Cancer
|
2005
|
1.20
|
|
36
|
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.
|
Gynecol Oncol
|
2004
|
1.15
|
|
37
|
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results.
|
J Nucl Med
|
2003
|
1.14
|
|
38
|
MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers.
|
Int J Cancer
|
2002
|
1.12
|
|
39
|
Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.11
|
|
40
|
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
|
Cancer
|
2006
|
1.07
|
|
41
|
Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer.
|
Gynecol Oncol
|
2006
|
1.05
|
|
42
|
Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?
|
Gynecol Oncol
|
2011
|
1.03
|
|
43
|
Frequent mutations in the RPL22 gene and its clinical and functional implications.
|
Gynecol Oncol
|
2012
|
1.03
|
|
44
|
Carcinosarcoma of the ovary-a case series.
|
Gynecol Oncol
|
2005
|
1.03
|
|
45
|
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer.
|
Cancer Res
|
2007
|
1.01
|
|
46
|
Paternal origins of complete hydatidiform moles proven by whole genome single-nucleotide polymorphism haplotyping.
|
Genomics
|
2002
|
1.01
|
|
47
|
DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis.
|
Mod Pathol
|
2006
|
0.99
|
|
48
|
Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer.
|
Clin Cancer Res
|
2013
|
0.99
|
|
49
|
Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era.
|
Gynecol Oncol
|
2008
|
0.98
|
|
50
|
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
|
Gynecol Oncol
|
2005
|
0.98
|
|
51
|
DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma.
|
Cancer
|
2010
|
0.97
|
|
52
|
Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer.
|
Gynecol Oncol
|
2002
|
0.96
|
|
53
|
Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.96
|
|
54
|
Cervical sarcomas: an analysis of incidence and outcome.
|
Gynecol Oncol
|
2005
|
0.96
|
|
55
|
The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies.
|
Gynecol Oncol
|
2002
|
0.96
|
|
56
|
Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.
|
Gynecol Oncol
|
2008
|
0.95
|
|
57
|
Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers.
|
Clin Cancer Res
|
2007
|
0.94
|
|
58
|
Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma.
|
Gynecol Oncol
|
2005
|
0.94
|
|
59
|
Bevacizumab therapy in patients with recurrent uterine neoplasms.
|
Anticancer Res
|
2007
|
0.94
|
|
60
|
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
|
Gynecol Oncol
|
2004
|
0.94
|
|
61
|
Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy.
|
Gynecol Oncol
|
2003
|
0.94
|
|
62
|
Antisense transcripts at the EMX2 locus in human and mouse.
|
Genomics
|
2003
|
0.93
|
|
63
|
Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
|
Gynecol Oncol
|
2008
|
0.93
|
|
64
|
Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2008
|
0.92
|
|
65
|
External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer.
|
Gynecol Oncol
|
2007
|
0.91
|
|
66
|
Ovarian cancer: to screen or not to screen.
|
Obstet Gynecol
|
2009
|
0.91
|
|
67
|
Posttherapy surveillance monitoring of cervical cancer by FDG-PET.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.91
|
|
68
|
Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
|
Cancer
|
2002
|
0.90
|
|
69
|
Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer.
|
Int J Gynecol Cancer
|
2012
|
0.90
|
|
70
|
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer.
|
Gynecol Oncol
|
2006
|
0.90
|
|
71
|
Expression profiling of mouse endometrial cancers microdissected from ethanol-fixed, paraffin-embedded tissues.
|
Am J Pathol
|
2003
|
0.89
|
|
72
|
The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy.
|
Cancer
|
2010
|
0.89
|
|
73
|
High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers.
|
Hum Mutat
|
2014
|
0.88
|
|
74
|
Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy.
|
J Genet Couns
|
2002
|
0.88
|
|
75
|
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
|
Ann Surg Oncol
|
2006
|
0.88
|
|
76
|
Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer.
|
Gynecol Oncol
|
2011
|
0.87
|
|
77
|
Synchronous ovarian metastases at the time of laparotomy for colon cancer.
|
Gynecol Oncol
|
2004
|
0.87
|
|
78
|
Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.87
|
|
79
|
Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer.
|
Gynecol Oncol
|
2012
|
0.86
|
|
80
|
Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation.
|
Clin Cancer Res
|
2004
|
0.86
|
|
81
|
Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers.
|
BMC Genomics
|
2014
|
0.86
|
|
82
|
Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas.
|
Gynecol Oncol
|
2010
|
0.85
|
|
83
|
Colposcopic accuracy of obstetrics and gynecology residents.
|
Gynecol Oncol
|
2006
|
0.85
|
|
84
|
"Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer.
|
Gynecol Oncol
|
2009
|
0.85
|
|
85
|
Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers.
|
Clin Cancer Res
|
2008
|
0.85
|
|
86
|
Cervical dysplasia in adolescents.
|
Obstet Gynecol
|
2005
|
0.85
|
|
87
|
Inferior vena cava filter placement in the gynecologic oncology patient: A 15-year institutional experience.
|
Gynecol Oncol
|
2011
|
0.85
|
|
88
|
Absence of MGMT promoter methylation in endometrial cancer.
|
Gynecol Oncol
|
2008
|
0.85
|
|
89
|
MLH3 mutation in endometrial cancer.
|
Cancer Res
|
2006
|
0.84
|
|
90
|
Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line.
|
Gynecol Oncol
|
2005
|
0.84
|
|
91
|
Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer.
|
Mol Cancer
|
2014
|
0.84
|
|
92
|
Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
|
Gynecol Oncol
|
2013
|
0.84
|
|
93
|
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
|
Gynecol Oncol
|
2013
|
0.84
|
|
94
|
Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy.
|
Radiat Med
|
2006
|
0.83
|
|
95
|
Human papillomavirus triage for young women with atypical squamous cells of undetermined significance.
|
Obstet Gynecol
|
2006
|
0.83
|
|
96
|
Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis.
|
Gynecol Oncol
|
2007
|
0.83
|
|
97
|
Lower uterine segment involvement is associated with poor outcomes in early-stage endometrioid endometrial carcinoma.
|
Ann Surg Oncol
|
2010
|
0.83
|
|
98
|
Long-term assessment of bladder and bowel dysfunction after radical hysterectomy.
|
Gynecol Oncol
|
2009
|
0.83
|
|
99
|
Treatment of high-risk gestational trophoblastic tumors.
|
Clin Obstet Gynecol
|
2003
|
0.82
|
|
100
|
Clinical and pathologic features of vulvar intraepithelial neoplasia in premenopausal and postmenopausal women.
|
J Low Genit Tract Dis
|
2011
|
0.81
|
|
101
|
Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.
|
Cancer Prev Res (Phila)
|
2012
|
0.81
|
|
102
|
Low allele frequency of MLH1 D132H in American colorectal and endometrial cancer patients.
|
Dis Colon Rectum
|
2005
|
0.81
|
|
103
|
Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer.
|
Radiat Med
|
2007
|
0.81
|
|
104
|
Wound complications after gynecologic cancer surgery.
|
Gynecol Oncol
|
2011
|
0.81
|
|
105
|
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
|
BMC Cancer
|
2014
|
0.81
|
|
106
|
Epithelial ovarian tumors of low malignant potential: the role of microinvasion.
|
Obstet Gynecol
|
2002
|
0.81
|
|
107
|
Update on prognostic markers for endometrial cancer.
|
Womens Health (Lond Engl)
|
2014
|
0.81
|
|
108
|
Lithium chloride and inhibition of glycogen synthase kinase 3β as a potential therapy for serous ovarian cancer.
|
Int J Gynecol Cancer
|
2013
|
0.80
|
|
109
|
FDG-PET evaluation of vaginal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.79
|
|
110
|
Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies.
|
Gynecol Oncol
|
2003
|
0.79
|
|
111
|
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
|
Gynecol Oncol
|
2006
|
0.79
|
|
112
|
Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery.
|
Gynecol Oncol
|
2006
|
0.79
|
|
113
|
Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
|
Int J Gynecol Cancer
|
2016
|
0.78
|
|
114
|
Targeted endometrial cancer therapy as a future prospect.
|
Womens Health (Lond Engl)
|
2013
|
0.78
|
|
115
|
Ovarian cancer patient surveillance after curative-intent initial treatment.
|
Gynecol Oncol
|
2011
|
0.78
|
|
116
|
The utility of peritoneal biopsy and omentectomy in the upstaging of apparent early ovarian cancer.
|
Int J Gynecol Cancer
|
2011
|
0.77
|
|
117
|
Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
|
Ann Surg Oncol
|
2013
|
0.77
|
|
118
|
The utility and management of vaginal cytology after treatment for endometrial cancer.
|
Obstet Gynecol
|
2013
|
0.77
|
|
119
|
Intestinal perforation in gynecologic oncology: do all patients benefit from surgical management?
|
Gynecol Oncol
|
2013
|
0.77
|
|
120
|
Gynecologic manifestations of hereditary nonpolyposis colorectal cancer. From inherited to sporadic disease.
|
Oncology (Williston Park)
|
2006
|
0.77
|
|
121
|
Racial disparities in uterine clear cell carcinoma: a multi-institution study.
|
Int J Gynecol Cancer
|
2014
|
0.77
|
|
122
|
The more things change the more they stay the same.
|
Gynecol Oncol
|
2011
|
0.77
|
|
123
|
Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.
|
Int J Gynecol Cancer
|
2013
|
0.77
|
|
124
|
In vitro chemoresponse to cisplatin and outcomes in cervical cancer.
|
Gynecol Oncol
|
2013
|
0.77
|
|
125
|
Gene therapy in gynecological cancer.
|
Expert Rev Anticancer Ther
|
2006
|
0.77
|
|
126
|
Cost-benefit of laparoscopic versus medical ovarian suppression in premenopausal breast cancer.
|
Breast J
|
2010
|
0.77
|
|
127
|
Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients.
|
Obstet Gynecol
|
2002
|
0.76
|
|
128
|
Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas.
|
Gynecol Oncol
|
2005
|
0.76
|
|
129
|
The risk of lymph node metastasis with positive peritoneal cytology in endometrial cancer.
|
Int J Gynecol Cancer
|
2013
|
0.76
|
|
130
|
Relationship of ovarian neoplasms and body mass index.
|
J Reprod Med
|
2005
|
0.76
|
|
131
|
Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
|
Gynecol Oncol
|
2007
|
0.76
|
|
132
|
Erratum: Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.
|
Sci Rep
|
2016
|
0.75
|
|
133
|
The value of perioperative imaging in patients with uterine sarcomas.
|
Gynecol Oncol
|
2009
|
0.75
|
|
134
|
Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
|
Int J Gynecol Cancer
|
2015
|
0.75
|
|
135
|
Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.
|
Int J Gynecol Cancer
|
2015
|
0.75
|
|
136
|
Disclosing a diagnosis of cancer: considerations specific to gynecologic oncology patients.
|
Obstet Gynecol
|
2013
|
0.75
|
|
137
|
Getting the message out: RNA interference of human papillomavirus.
|
Reprod Sci
|
2007
|
0.75
|
|
138
|
SGO future forward: Our greatest challenges are our greatest opportunities.
|
Gynecol Oncol
|
2010
|
0.75
|
|
139
|
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
|
Gynecol Oncol
|
2006
|
0.75
|
|
140
|
Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases.
|
Int J Gynecol Cancer
|
2017
|
0.75
|
|
141
|
A Transperineal Approach to Hysterectomy of a Retained Didelphic Uterine Horn.
|
Obstet Gynecol
|
2017
|
0.75
|
|
142
|
Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study.
|
Invest New Drugs
|
2002
|
0.75
|
|
143
|
Survival of Cervical Cancer Patients Presenting with Occult Supraclavicular Metastases Detected by FDG-Positron Emission Tomography/CT: Impact of Disease Extent and Treatment.
|
Gynecol Obstet Invest
|
2017
|
0.75
|
|
144
|
Wound Complication Rates After Staples or Suture for Midline Vertical Skin Closure in Obese Women: A Randomized Controlled Trial.
|
Obstet Gynecol
|
2017
|
0.75
|
|
145
|
Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms.
|
Gynecol Oncol
|
2004
|
0.75
|
|
146
|
A vascular graft for endometrial cancer groin recurrence.
|
Gynecol Oncol
|
2006
|
0.75
|
|
147
|
Postradiation damage to the pelvic girdle in cervical cancer patients: is intensity-modulated radiation therapy safer than conventional radiation?
|
Int J Gynecol Cancer
|
2014
|
0.75
|
|
148
|
Etiology and workup of fevers in gynecologic oncology patients.
|
Int J Gynecol Cancer
|
2014
|
0.75
|
|
149
|
Hemolytic uremic syndrome presenting after treatment of endodermal sinus tumor.
|
Obstet Gynecol
|
2004
|
0.75
|
|
150
|
Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer.
|
Gynecol Oncol
|
2007
|
0.75
|